Tumours harness CIN and point mutations to evolve genetic heterogeneity, the key reason for the poor survival of cancer patients.
We develop the first personalised medicines to treat heterogeneous cancers.
We discover drug targets essential for tumours to survive the consequences of CIN.
We tackle the challenge of distinguishing these targets and defining their respective patient selection molecular markers.
Enedra’s platform uses the power of advanced computational and genomic science to discover the first precision medicines, that are effective despite the biological complexity of heterogenous cancers.
Enedra is developing a pipeline of programs on multiple novel cancer agnostic targets, currently at the discovery stage.
CEO of two successful ventures: Diadem (Alzheimer's Dx) and HRM (cell therapy). Background in Pharma corporate business development and investment at Alapis Pharma. R&D expertise in single-cell-omics target discovery at AstraZeneca.
Former CEO of Storm Therapeutics and Cancer Research Technology, with experience in licensing, drug discovery and fundraising. Former director at KuDOS Pharmaceuticals, Mission Therapeutics and Inivata Ltd.
Head of Medicinal Chemistry
Scientific co-founder of Monte Rosa Therapeutics. World leading medicinal chemist.Discoveredmultiple novel cancer clinical candidates. Ex Head of Chemistry at the Institute for Cancer Research.
Head of Drug Discovery
Co-raised significant series A round as VP Drug Discovery Entact Bio. Ex Deputy Director of Drug Discovery, Cancer Research Technology. Leading expert in building drug discovery platforms.
Executive Director at Charles River. Director Discovery Medicine AZ, Head of Drug Discovery at MICR CRUK.
Associate Professor at ICR. Enedra VP of Technology.
Expert in AI, systems biology for drug discovery. Pioneered multi-omic subtyping of cancer with Joe Gray and Doug Hanahan. Associate Professor at ICR. Seconded as Enedra VP of Technology. Anguraj co-developed our computational platform.
Bioinformatics Lead of the CRUK-UCL Lung Cancer Centre of Excellence and TRACERx team.
Leading expert in tumour evolution.
Director of Computational Biology at Lonza, GSK Scientific Lead for Open Targets.
Expert in computational biology for target identification. Ex. Director of Computational Biology at Lonza, GSK Scientific Lead for Open Targets, Bringing his experience with project Score, Alex co-developed key aspects of the platform.
CASPAROV platform: allowing the move from heterogeneous disease to personalised medicines